Design, synthesis, biological evaluation and molecular docking study on peptidomimetic analogues of XK469

• DOI: 10.1016/j.ejmech.2016.08.010
• Publication Date: 2016-08-10T19:00:38Z
• Authors: Qiao-Hong Xia; Wei Hu; Chen Li; Ji-Feng Wu; Liang Yang; Xue-Mei Han; Yue-Mao Shen; Zhi-Yu Li; Xun Li
• Keywords: 0303 health sciences; Protein Conformation; Antineoplastic Agents; Chemistry Techniques, Synthetic; DNA; Xenograft Model Antitumor Assays; 3. Good health; Molecular Docking Simulation; Mice; Structure-Activity Relationship; 03 medical and health sciences; DNA Topoisomerases, Type II; Drug Design; Quinoxalines; Animals; Humans; Peptidomimetics; Neoplasm Metastasis; Cell Proliferation

XK469 is identified as a potent quinoxaline antineoplastic agent based on its significant clinical efficacy. It probably exerts its activity via DNA topoisomerase II (topo II) inhibition. To obtain more effective antineoplastic agents, a spectrum of peptidomimetic-type quinoxaline analogues of XK469 was herein designed, synthesized, and evaluated. Few compounds (e.g. 13a and 13b) exhibited obvious cytotoxicity indicated by in vitro anti-proliferative assay. SAR investigation revealed that introducing of hydrophobic tert-butylamine or dodecylamine moiety at the 3-position of quinoxaline core is favorable for achieving a better anti-proliferative potency, while peptidomimetic derivatives only yielded moderate cytotoxicity. Compounds with improved anti-proliferative activities also demonstrated decent anti-metastatic potencies comparable with that of doxorubicin (Doxo) based on in vivo mouse model study. The topo II-mediated kinetoplast DNA (kDNA) decatenation assay as well as molecular docking studies implicated that these compounds tend to be potent topo II inhibitors. Overall, compounds 13a and 13b, 13b in particular, standed out from various assessments and might be promising candidates for further chemical optimization.